Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

EyePoint Pharmaceuticals (EYPT) EBITDA Margin: 2010-2018

Historic EBITDA Margin for EyePoint Pharmaceuticals (EYPT) over the last 8 years, with Sep 2018 value amounting to -6,816.05%.

  • EyePoint Pharmaceuticals' EBITDA Margin fell 526306.00% to -6,816.05% in Q3 2018 from the same period last year, while for Sep 2018 it was -3,603.10%, marking a year-over-year decrease of 337677.00%. This contributed to the annual value of -1,795.54% for FY2018, which is 155010.00% down from last year.
  • As of Q3 2018, EyePoint Pharmaceuticals' EBITDA Margin stood at -6,816.05%, which was down 41.56% from -4,814.97% recorded in Q2 2018.
  • EyePoint Pharmaceuticals' EBITDA Margin's 5-year high stood at 81.06% during Q3 2014, with a 5-year trough of -6,816.05% in Q3 2018.
  • Moreover, its 3-year median value for EBITDA Margin was -1,559.57% (2016), whereas its average is -2,520.31%.
  • Data for EyePoint Pharmaceuticals' EBITDA Margin shows a peak YoY increase of 123,967bps (in 2017) and a maximum YoY decrease of 578,163bps (in 2017) over the last 5 years.
  • EyePoint Pharmaceuticals' EBITDA Margin (Quarterly) stood at -791.36% in 2014, then tumbled by 19,932bps to -990.68% in 2015, then surged by 98,931bps to -1.37% in 2016, then crashed by 578,163bps to -5,783.00% in 2017, then tumbled by 526,306bps to -6,816.05% in 2018.
  • Its EBITDA Margin was -6,816.05% in Q3 2018, compared to -4,814.97% in Q2 2018 and -751.83% in Q1 2018.